Investigational Alzheimer’s Drug Improves Biomarkers of the Disease
Gantenerumab, an investigational drug for Alzheimer’s disease, reduced amyloid plaques and lowered tau levels in the brains of people with genetic risk factors for the neurodegenerative disorder.